Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | HTR6 | P50406 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28328314 | 0.92 | HTR6 (0.44) | HTR6HTR2C | |
| SCHEMBL27150738 | 0.84 | HTR2C (0.59) | HTR6HTR2C | |
| SCHEMBL28035679 | 0.84 | PTGS2 (0.42) | PTGS2HTR6HTR2C | |
| SCHEMBL1046363 | 0.83 | PTGES2 (0.51) | PTGES2PTGS2 | |
| SCHEMBL20541539 | 0.82 | PTGES2 (0.45) | PTGES2PTGS2 | |
| SCHEMBL28163309 | 0.82 | PTGES2 (0.45) | PTGES2PTGS2 | |
| SCHEMBL16947752 | 0.81 | PTGES2 (0.49) | PTGES2PTGS2 | |
| SCHEMBL23664866 | 0.80 | PTGS2 (0.44) | PTGS2HTR6HTR2C | |
| SCHEMBL20674413 | 0.80 | PTGES2 (0.43) | PTGES2PTGS2 | |
| Hydrochloric Acid SCHEMBL7254235 | 0.80 | PTGES2 (0.48) | PTGES2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | PTGES2 161/4885PTGS2 312/4885HTR6 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.